Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
Kinpeygo, which was granted conditional marketing authorisation in EU on
"This is an important day for patients suffering from IgAN in
The CHMP's positive opinion will now be forwarded to the
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information in the report is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact person set out above, on
About Calliditas
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Calliditas' strategy, commercialization efforts, business plans, regulatory submissions, clinical development plans, revenue and product sales projections or forecasts and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas' business, operations, EC authorization for full approval of Kinpeygo, continued and additional regulatory approvals for TARPEYO and Kinpeygo, market acceptance of TARPEYO and Kinpeygo, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other biopharmaceutical companies, revenue and product sales projections or forecasts and other risks identified in the section entitled "Risk Factors" in Calliditas' reports filed with the
This information was brought to you by Cision http://news.cision.com
The following files are available for download
EMA Positive Opinion PR_ENG |
View original content:https://www.prnewswire.co.uk/news-releases/calliditas-partner-stada-receives-positive-chmp-opinion-recommending-full-approval-for-kinpeygo-for-the-treatment-of-iga-nephropathy-302159841.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN27621&Transmission_Id=202405301420PR_NEWS_EURO_ND__EN27621&DateId=20240530)